Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics

体内分布 化学 抗体 体外 癌症研究 体内 分子生物学 癌症 胰腺癌 Pet成像 共轭体系 拉顿 融合蛋白 流式细胞术 肿瘤细胞 细胞毒性 细胞培养 癌细胞 抗原 显像剂 核医学 病理 药代动力学
作者
Wenyu Wu,Guoqiang Shao,Yilin Xue,Jun Chen,Zhaoyang Zhao,Jingjing Fu,Rui Yang,Hai Qian,Chaowei Hao
出处
期刊:Molecular Pharmaceutics [American Chemical Society]
卷期号:23 (11): 5946-5955
标识
DOI:10.1021/acs.molpharmaceut.6c01174
摘要

Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2-50H and VHH-Fc fusion antibody 18.2-50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2-50H, and 18.2-50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2-50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
一抹火烧云完成签到,获得积分10
1秒前
深情安青的应助被奔跑少年采纳,获得10
1秒前
欢喜灵13发布了新的文献求助10
2秒前
感谢大家发布了新的文献求助10
2秒前
动听海秋发布了新的文献求助10
2秒前
3秒前
汉堡包的应助被美满乐荷采纳,获得10
3秒前
无极微光的应助被Yutong采纳,获得50
3秒前
风吹麦浪发布了新的文献求助10
3秒前
3秒前
3秒前
搜集达人的应助被QUPY采纳,获得10
3秒前
沉默小玉完成签到,获得积分10
4秒前
fanjia完成签到,获得积分10
4秒前
田乐天完成签到 ,获得积分10
4秒前
知性的沂完成签到,获得积分10
4秒前
伶俐子默发布了新的文献求助10
5秒前
万能图书馆的应助被sincerely采纳,获得10
5秒前
5秒前
5秒前
6秒前
7秒前
阿呸完成签到,获得积分10
7秒前
yuxyu完成签到 ,获得积分10
7秒前
huhuhaoshuai发布了新的文献求助10
7秒前
7秒前
7秒前
杪春发布了新的文献求助10
8秒前
林读书发布了新的文献求助10
8秒前
阿杳完成签到 ,获得积分10
8秒前
王旭完成签到,获得积分10
9秒前
ZZ完成签到,获得积分20
9秒前
时s完成签到,获得积分10
9秒前
10秒前
10秒前
感谢大家完成签到,获得积分10
10秒前
001发布了新的文献求助10
10秒前
bbllxyl完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181949
求助须知:如何正确求助?哪些是违规求助? 9571702
关于积分的说明 21819272
捐赠科研通 7778399
什么是DOI,文献DOI怎么找? 3433572
关于科研通互助平台的介绍 2557769
邀请新用户注册赠送积分活动 2479630